Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/13/2021 10/14/2021 10/15/2021 10/18/2021 10/19/2021 Date
43.9(c) 45.47(c) 39.82(c) 40.98(c) 42.1 Last
637 921 824 872 2 268 415 826 875 356 317 Volume
+6.61% +3.58% -12.43% +2.91% +2.73% Change
More quotes
Estimated financial data (e)
Sales 2021 147 M 170 M 170 M
Net income 2021 -325 M -378 M -378 M
Net cash position 2021 1 446 M 1 682 M 1 682 M
P/E ratio 2021 -17,9x
Yield 2021 -
Sales 2022 4 087 M 4 755 M 4 755 M
Net income 2022 2 201 M 2 561 M 2 561 M
Net cash position 2022 5 533 M 6 438 M 6 438 M
P/E ratio 2022 2,29x
Yield 2022 -
Capitalization 6 407 M 7 440 M 7 454 M
EV / Sales 2021 33,9x
EV / Sales 2022 0,21x
Nbr of Employees 505
Free-Float 48,7%
More Financials
Company
CureVac AG is a Germany-based biotechnology company. The Company is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The Company's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies. 
More about the company
Ratings of CureVac N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CUREVAC N.V.
10/18CUREVAC N : Shareholder dievini Files Shareholding Change with US Regulator; Stock Down 5%
MT
10/18PRESS RELEASE : dievini explains reasons for changes in shareholdings in CureVac due to le..
DJ
10/15CureVac Shares Down 12%
DJ
10/13CUREVAC N : EMA ends rolling review of CVnCoV COVID-19 vaccine following withdrawal by Cur..
AQ
10/12CLOSE UPDATE : US Stocks Waver Ahead of Earnings, FOMC Minutes; Investors Remain Cautious ..
MT
10/12Health Care Stocks Extending Retreat Ahead of Tuesday Close
MT
10/12Equities Choppy Midday as Clarida Says Fed Would Respond to Rise in Inflation Expectati..
MT
10/12MIDDAY REPORT : US Stocks Choppy as Clarida Says Fed Would Respond to Rise in Inflation Ex..
MT
10/12Health Care Stocks Falling Despite Moderate Rise Among Biotech Companies
MT
10/12CUREVAC N : Drops COVID-19 Vaccine to Focus on Second-Generation Shot with GlaxoSmithKline
MT
10/12Wall Street Set for Cautiously Higher Open, Earnings Season Eyed
MT
10/12Health Care Stocks Edge Higher Premarket Tuesday
MT
10/12WALL STREET STOCK EXCHANGE : It's just a period of market normalization
10/12CUREVAC N : to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Techn..
PU
10/12CUREVAC N : Forgoes COVID-19 Vaccine Candidate; Stock Slips 15%
MT
More news
News in other languages on CUREVAC N.V.
11:01aCOVID : Curevac retire sa demande d'examen d'un vaccin auprès de Swissmedic
10/18Dievini erläutert Hintergrund für Veränderungen im Anteilsbesitz an CureVac aufgrund vo..
10/15PRESSESPIEGEL/Unternehmen
10/14Erste Betriebsratswahl bei Curevac
10/14CUREVAC : la pharma abandonne son candidat-vaccin Covid et rejoint ls recherches de GSK
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | CVAC | NL0015436031 | MarketScreener
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 35,29 €
Average target price 65,23 €
Spread / Average Target 84,8%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean Stéphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-49.45%7 440
MODERNA, INC.220.51%135 157
LONZA GROUP AG27.29%58 232
IQVIA HOLDINGS INC.38.67%47 608
SEAGEN INC.-1.81%31 287
CELLTRION, INC.-39.69%24 952